Novartis AG (NVS) annual results, year to 31 December 2020: revenue USD 48,659 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2020 it reported revenue from the sale of goods of USD 48,659 million, up 2.4% on the year before. Its profit attributable to shareholders was USD 8,072 million, down 31.2%, and diluted earnings per share USD 3.52.
The year to 31 December 2020, against the year before
| Year to | Dec 2019 | Dec 2020 † |
|---|---|---|
| Revenue from the sale of goods | 47,498 | 48,659 |
| Cost of sales | 14,425 | 15,121 |
| Gross profit | 34,252 | 34,777 |
| Research and development | 9,402 | 8,980 |
| Selling, general and administrative | 14,369 | 14,197 |
| Operating profit | 9,086 | 10,152 |
| Profit before tax | 8,940 | 9,878 |
| Income tax | 1,793 | 1,807 |
| Profit for the year | 11,737 | 8,071 |
| Profit attributable to shareholders | 11,732 | 8,072 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2019 | Dec 2020 † |
|---|---|---|
| Cash from operations | 13,625 | 13,650 |
| Purchase of property, plant and equipment | 1,379 | 1,275 |
| Free cash flow | 12,246 | 12,375 |
| Dividends paid | 6,645 | 6,987 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2019 | Dec 2020 † |
|---|---|---|
| Total assets | 118,370 | 127,778 |
| Equity attributable to shareholders | 55,474 | 56,598 |
| Cash and cash equivalents | 11,112 | 9,658 |
| Borrowings, as filed | 22,355 | 28,531 |
| Lease liabilities | 1,949 | 2,005 |
| Inventories | 5,982 | 7,131 |
| Goodwill | 26,524 | 29,999 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2019 | Dec 2020 † |
|---|---|---|
| Return on year-end equity | 21.1% | 14.3% |
| Effective tax rate | 20.1% | 18.3% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020, this page
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
Source
20-F for the year to 31 December 2020, filed 15 May 2023, accession 0001370368-23-000048: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.